Neuraminidase inhibitors work by binding to the active site of the enzyme, preventing it from cleaving sialic acid residues. This inhibition impedes the release of new viral particles from the host cell, thereby limiting the spread of the virus. These inhibitors are crucial in the treatment and prevention of influenza infections. However, their use raises concerns about potential drug resistance, necessitating ongoing toxicological evaluations.
